About GLP-1–Based Weight-Loss Medications
What Are GLP-1 Medications?
GLP-1 receptor agonists mimic glucagon-like peptide-1, a hormone released after eating. Tirzepatide activates both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. These medicines act in the brain, pancreas, stomach, intestine, and other tissues.
How They Work
- Reduce hunger, cravings, and “food noise” through brain appetite pathways
- Increase fullness and help smaller portions feel satisfying
- Slow stomach emptying, especially early in treatment
- Increase glucose-dependent insulin release and reduce inappropriate glucagon signaling
- Improve blood glucose and insulin sensitivity, partly through weight loss
- May improve blood pressure, triglycerides, sleep apnea, liver disease, cardiovascular risk, and other weight-related conditions in appropriately selected patients
FDA-Approved Weight-Loss Medications
Several medications have been approved by the U.S. Food and Drug Administration (FDA) to help with long-term weight management. Each works differently and varies in effectiveness, dosing schedule, side effects, and eligibility. Your APNS provider can help determine which option may be appropriate based on your health history and treatment goals.
| Medication | Form / Frequency | Typical Trial Weight Loss* | Advantages | Disadvantages / Limits |
|---|---|---|---|---|
| Zepbound® (tirzepatide) | Weekly injection; dual GIP/GLP-1 agonist | About 20% at 72 weeks in the head-to-head SURMOUNT-5 trial at maximum tolerated doses; individual results vary. | Highest average loss among currently approved incretin obesity medicines; approved for obesity/overweight and for moderate-to-severe obstructive sleep apnea in adults with obesity. | GI effects; cost/access; injection; tirzepatide can reduce oral contraceptive exposure during initiation and dose escalation. |
| Wegovy® injection (semaglutide) | Weekly injection; GLP-1 agonist | About 14% in SURMOUNT-5 and approximately 15% in STEP 1 at 68–72 weeks; higher 7.2 mg dose has separate trial data and eligibility. | Extensive outcomes data; reduces major cardiovascular events in adults with established cardiovascular disease and overweight/obesity; also has a MASH indication for selected adults. | GI effects; injection; cost/access; retinopathy monitoring in diabetes; rare eye-risk signal remains under study. |
| Wegovy® tablet (semaglutide 25 mg) | FDA-approved once-daily oral tablet | Approximately low-to-mid teens in pivotal obesity trials, depending on analysis and adherence. | Avoids injections; FDA-approved formulation with obesity and cardiovascular indications. | Strict administration instructions; daily dosing; GI effects; not equivalent to compounded drops, troches, or sprays. |
| Saxenda® (liraglutide) | Daily injection; GLP-1 agonist | Approximately 8% at 56 weeks in pivotal trials. | Long clinical experience; daily dosing can allow faster discontinuation if poorly tolerated; approved for certain adolescents. | Daily injection; generally less weight loss than semaglutide or tirzepatide; GI effects and cost. |
Note: *Average trial results reflect specific populations, doses, adherence, lifestyle programs, and follow-up periods. They are not guarantees and should not be compared directly across unrelated trials without caution.
Retatrutide: An Investigational Triple Agonist
Retatrutide is an investigational once-weekly medication developed by Eli Lilly that activates three hormone receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling may reduce appetite and improve glucose-dependent metabolic signaling, while glucagon-receptor activity is being studied for possible effects on energy expenditure, liver fat, and metabolism. This “triple-agonist” design may produce greater average weight loss than currently approved single- or dual-agonist medicines, but direct comparisons and long-term outcome data are still needed.
| Study / Population | Result | How to Interpret It |
|---|---|---|
| TRIUMPH-1 Phase 3; adults with obesity or overweight plus a weight-related condition, without type 2 diabetes | At 12 mg, average loss was 28.3% at 80 weeks; 45.3% of participants lost at least 30%. | These are company-reported pivotal topline results. Approximately 28%—not 30%—was the overall 80-week average at the highest studied dose. |
| TRIUMPH-1 extension; participants with baseline BMI ≥35 | Average loss reached 30.3% at 104 weeks in the 12 mg extension group. | The approximately 30% average was reported after two years in a higher-BMI extension population, not the entire 80-week study population. |
| TRIUMPH-4; obesity/overweight with knee osteoarthritis | At 12 mg, average loss was 28.7% at 68 weeks with major average improvement in knee discomfort and function. | Results support substantial efficacy but do not establish FDA approval or availability. |
The most common reported adverse effects have been gastrointestinal—nausea, diarrhea, vomiting, and constipation—and appear dose-related. Dysesthesia or abnormal skin sensations has also been reported. Retatrutide is not FDA-approved as of July 2026. It should not be purchased as “research peptide,” compounded, or prescribed as though it were an approved medication; products marketed online may be counterfeit, contaminated, incorrectly dosed, or not retatrutide.
Diabetes Medications and Weight Loss
Several medications used to treat type 2 diabetes contain the same or similar active ingredients as FDA-approved weight-loss medications. However, diabetes and obesity products have different FDA indications, dosing schedules, and insurance coverage requirements, and they should not be considered interchangeable.
| Brand | Ingredient | FDA Indication | Weight-Loss Consideration |
|---|---|---|---|
| Mounjaro® | Tirzepatide | Type 2 diabetes | Same active ingredient as Zepbound but labeled for diabetes. Doses and coverage rules must follow the prescribed product. |
| Ozempic® | Semaglutide injection | Type 2 diabetes and cardiovascular/kidney risk indications in selected adults | Not the obesity-labeled semaglutide product; diabetes-dose trial results should not be represented as Wegovy results. |
| Rybelsus® | Oral semaglutide | Type 2 diabetes | Not the same product or dose as FDA-approved oral Wegovy. |
| Victoza®, Trulicity®, Byetta®/Bydureon® | Liraglutide, dulaglutide, exenatide | Type 2 diabetes | May cause weight loss but are not FDA-approved obesity products. |
Compounded Products
Compounded semaglutide or tirzepatide is not an FDA-approved generic equivalent. The FDA does not review a compounded product for safety, effectiveness, quality, dose accuracy, or bioequivalence before marketing. Compounded oral drops, sublingual products, troches, sprays, microdoses, added vitamins, or nonstandard concentrations have not been shown to produce the same weight loss as FDA-approved injections or tablets.Expectation for Nonstandard Oral or Microdose Products
A patient using a compounded oral formulation or the lowest dose should not expect the same rate or extent of weight loss reported with full-dose weekly injections or FDA-approved oral Wegovy. Some nonstandard formulations have not been empirically tested in controlled weight-loss trials.
Who May Qualify for GLP-1 Treatment?
General FDA Weight Criteria for Adults
- BMI of 30 kg/m² or higher; or
- BMI of 27 kg/m² or higher with at least one weight-related condition, such as hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease.
- Product-specific pediatric criteria differ and are outside APNS adult specialty-care scope unless APNS establishes a separate pediatric pathway.
BMI is imperfect. A clinician may also consider waist circumference, body composition, ethnicity, weight trajectory, metabolic complications, sarcopenia, prior treatment, and the purpose of therapy. However, prescribing outside FDA weight criteria is off label and requires an individualized rationale
FDA-Labeled BMI Eligibility for Weight-Loss Medications
The FDA approves weight-loss medications based on specific BMI thresholds and, in some cases, the presence of weight-related medical conditions. Meeting these criteria does not automatically mean a medication is appropriate, as treatment decisions also depend on an individual’s health history, contraindications, and clinical evaluation.
| Adult BMI | Comorbidity Needed? | FDA-Labeled Weight-Management Eligibility |
|---|---|---|
| Below 25 kg/m² | Not applicable | Not within the labeled BMI indication for Wegovy, Zepbound, or Saxenda solely for weight management. |
| 25.0–26.9 kg/m² | Even with a comorbidity, current obesity-product labeling generally does not qualify the patient. | Treatment through a private or compounded program may use different criteria, but this is off label and is not an FDA guideline. |
| 27.0–29.9 kg/m² | Yes—at least one weight-related comorbid condition | Meets the labeled BMI pathway when a qualifying weight-related condition is present. |
| 27.0–29.9 kg/m² | No | Does not meet the standard FDA-labeled weight-management indication. |
| 30.0 kg/m² or higher | No additional comorbidity required | Meets the labeled BMI pathway for adult obesity, subject to product-specific contraindications and clinical assessment. |
Florida and New Jersey
The FDA BMI criteria are national; Florida and New Jersey do not have a separate FDA threshold. Florida rules add obesity-treatment assessment, documentation, and follow-up requirements. New Jersey adds evaluation, informed-consent, monitoring, and—within some telehealth programs—mental-health screening and semiannual check-ins. Insurance plans may impose their own prior-authorization rules.
Weight-Related Comorbidities
For adults with a BMI between 27.0 and 29.9 kg/m², FDA labeling for many weight-loss medications generally requires at least one qualifying weight-related medical condition. The examples below illustrate commonly recognized comorbidities, although insurance coverage and documentation requirements may vary.
| Category | Examples | Eligibility Note |
|---|---|---|
| Explicit examples in FDA obesity-product labeling | Hypertension; type 2 diabetes; dyslipidemia or high cholesterol. | These are repeatedly listed as examples of weight-related comorbid conditions. |
| Other commonly accepted weight-related conditions | Obstructive sleep apnea; established cardiovascular disease; metabolic dysfunction-associated steatotic liver disease; osteoarthritis or mobility-limiting joint disease. | Clinically weight related, but insurer and product documentation requirements vary. |
| Often considered metabolically relevant | Prediabetes; insulin resistance; polycystic ovary syndrome; metabolic syndrome. | May support clinical rationale, but not every insurer treats each as a qualifying condition. |
| Not enough by itself | A desire to lose weight, family history alone, or a cosmetic goal without the required BMI/condition. | Does not meet standard labeled eligibility. |
Eligibility and Safety Review
Before prescribing a weight-loss medication, healthcare providers review a patient’s medical history, current health conditions, and potential risk factors. Certain conditions may make a medication inappropriate, while others simply require additional evaluation, monitoring, or specialist involvement.
| History or Finding | How It Should Be Handled |
|---|---|
| Personal or family history of medullary thyroid carcinoma (MTC) | Do not use semaglutide, tirzepatide, or liraglutide obesity products under current boxed warnings. |
| Personal or family history of MEN2 | Do not use under current labeled contraindications. MEN2—not every MEN syndrome—is the relevant boxed-warning condition. |
| Prior serious allergy to the drug or ingredients | Do not use that product. Symptoms of anaphylaxis require emergency care. |
| Pregnant or planning pregnancy | Weight-loss therapy is inappropriate. Stop when pregnancy is recognized. Semaglutide is generally stopped at least 2 months before a planned pregnancy; follow the specific product label. |
| Breastfeeding | Generally avoid for weight loss unless product-specific evidence and a clinician’s individualized assessment support use. APNS may exclude as a practice policy. |
| Type 1 diabetes | Not indicated for weight management as a substitute for insulin; risk of hypoglycemia or ketoacidosis with inappropriate insulin changes. Requires diabetes-specialist management and may be outside APNS program scope. |
| Prior pancreatitis | Not a universal FDA-labeled absolute contraindication, but recurrence concern warrants careful review; many telehealth programs exclude or require specialist input. |
| Gastroparesis or severe gastrointestinal motility disorder | Generally avoid; GLP-1–based drugs are not recommended in severe gastroparesis and may worsen symptoms. |
| Severe constipation, ileus, bowel obstruction, or IBS with constipation | Assess severity and cause. Active ileus/obstruction or severe motility disease is inappropriate; stable mild constipation may be managed with monitoring rather than being an automatic class contraindication. |
| Inflammatory bowel disease | Not an automatic class contraindication, but active disease, obstruction, severe symptoms, dehydration, or complex medication use may require gastroenterology review. |
| Prior GI or bariatric surgery | Not automatically disqualifying. Recent surgery, complications, altered anatomy, obstruction risk, malnutrition, or oral-drug absorption concerns require individualized review. |
| Gallstones or gallbladder disease | GLP-1 therapy and rapid weight loss may increase gallbladder events. Active or complicated disease requires evaluation; remote stable disease is a precaution, not always an absolute exclusion. |
| Hepatitis, elevated liver enzymes, MASLD/MASH, or cirrhosis | Elevated enzymes or fatty liver are not automatic contraindications; semaglutide has a selected MASH indication. Acute hepatitis, decompensated cirrhosis, unexplained major elevations, or severe impairment require in-person/specialist evaluation. |
| Kidney disease | Dose adjustment may not be required for some products, but vomiting/diarrhea can cause dehydration and acute kidney injury. Severe or unstable disease requires close monitoring. |
| Diabetic retinopathy | Not an absolute contraindication. Rapid glucose improvement can temporarily worsen retinopathy in some patients; baseline eye care and monitoring are important. |
| Seizure disorder | Not a class contraindication to GLP-1 therapy, but vomiting, dehydration, hypoglycemia, or altered absorption of seizure medication may destabilize control. Seizures are especially relevant when considering bupropion-containing therapy. |
| Eating disorder, alcohol misuse, or substance-use disorder | Requires careful assessment. Active eating disorders are generally inappropriate for routine weight-loss prescribing; medication choice depends on psychiatric and substance history. |
| Planned anesthesia, deep sedation, or surgery | Tell the procedural team. Do not use a universal stop interval without their instructions; management depends on medication, dose escalation, symptoms, fasting, and procedure risk. |
APNS Program Criteria vs. Drug Contraindications
APNS may choose stricter program exclusions than the FDA label because asynchronous telehealth cannot safely manage every condition.
Managing Common GLP-1 Side Effects
Constipation
Constipation occurs because these medications can slow stomach emptying and intestinal transit. Prevention and early treatment are important.- Increase fiber gradually toward approximately 25–30 grams per day using vegetables, fruit, legumes, and whole grains, unless a clinician has advised a low-fiber diet.
- Drink enough fluid to maintain pale urine—often around 64 ounces daily, but fluid targets must be individualized for heart or kidney disease.
- Consider a soluble-fiber supplement such as psyllium (Metamucil®) or wheat dextrin (Benefiber®), beginning gradually.
- If appropriate, an osmotic laxative such as polyethylene glycol (MiraLAX®) is often more effective for slow-transit constipation than a stool softener alone. Senna may be used short term when appropriate.
- Contact APNS if constipation persists, worsens, or recurs with each dose increase. The medication may need to be held, reduced, or stopped.
No Bowel Movement for More Than 2 Days
Contact APNS and begin the clinician-approved constipation plan rather than waiting for severe symptoms. Do not keep escalating laxatives or fiber if there is severe abdominal discomfort, vomiting, marked swelling, inability to pass gas, or suspected obstruction—stop the medication and seek urgent in-person evaluation.
Nausea, Fullness, and Heartburn
- Eat slowly and stop at the first sign of fullness.
- Use smaller meals; avoid lying down soon after eating.
- Avoid fried, greasy, very fatty, spicy, or high-sugar foods during symptomatic periods.
- Choose bland, light foods and clear or cold fluids as tolerated.
- Separate food and large volumes of fluid if fullness is severe, while maintaining total hydration.
- Discuss prescription or over-the-counter anti-nausea or reflux treatment with the clinician rather than masking persistent symptoms.
- For injectable products, rotating to the thigh may help some patients, although evidence that injection site consistently changes systemic side effects is limited.
Briefly smelling an isopropyl-alcohol pad has been studied for short-term nausea relief in supervised acute-care settings. It should be held several centimeters away, not placed on the skin under the nose, inhaled continuously, used in a poorly ventilated area, or relied upon for persistent medication intolerance.
Diarrhea
- Replace fluids throughout the day and consider an oral electrolyte solution if losses are substantial.
- Temporary soluble fiber may help bulk stool.
- Avoid very fatty foods, excess alcohol, and foods that clearly worsen symptoms.
- If diarrhea persists for about 48 hours, contact APNS before using loperamide (Imodium®), especially if there is fever, blood, severe discomfort, possible infection, medication interactions, or risk of constipation.
Belching, Gas, and Bloating
Smaller portions, slower eating, avoiding carbonated beverages, and limiting trigger foods may help. Simethicone (Gas-X®) may relieve gas but will not correct gastroparesis, obstruction, or severe medication intolerance.
Fatigue
Fatigue may reflect reduced calorie or protein intake, dehydration, sleep disruption, rapid weight loss, anemia, thyroid disease, low blood pressure, or another condition. Vitamin B12 is helpful when intake is inadequate or deficiency is present, but it is not a universal treatment for GLP-1 fatigue.
Injection-Site Reactions
Rotate sites and avoid irritated skin. Allowing a refrigerated pen to sit at room temperature for the product-approved period may reduce discomfort. Mild itching or redness may respond to a cool compress or clinician-approved topical hydrocortisone. Hives, facial swelling, breathing difficulty, or a spreading reaction requires immediate discontinuation and urgent care.
APNS Program Criteria vs. Drug Contraindications
APNS may choose stricter program exclusions than the FDA label because asynchronous telehealth cannot safely manage every condition.
Serious Risks and When to Seek Care
Stop the Medication and Go to the Emergency Room Immediately For
- Sudden vision loss, a new dark area or curtain in vision, or a sudden major vision change
- Severe or persistent abdominal discomfort—especially if radiating to the back—with or without vomiting
- Severe abdominal swelling, repeated vomiting, inability to pass stool or gas, or suspected bowel obstruction
- Trouble breathing or swallowing, swelling of the face, lips, tongue, or throat, fainting, or other signs of anaphylaxis
- Severe dehydration, confusion, very low urine output, or fainting
Pancreatitis
Pancreatitis can cause severe upper abdominal discomfort that may radiate to the back, often with nausea or vomiting. Stop treatment and obtain urgent evaluation. Do not restart unless the prescriber determines it is appropriate.
Gallbladder Disease
Rapid weight loss and GLP-1–based therapy can increase the risk of gallstones or gallbladder inflammation. Seek prompt care for right-upper abdominal discomfort, fever, jaundice, clay-colored stool, or persistent vomiting.
Severe GI Motility Problems
GLP-1–based medications delay gastric emptying and may worsen severe gastroparesis or intestinal motility disorders. Persistent vomiting, prolonged inability to eat, severe constipation, inability to pass gas, or significant abdominal swelling is not a normal side effect to “push through.”
Kidney Injury and Dehydration
Vomiting and diarrhea can reduce blood volume and kidney perfusion. Contact APNS early if fluids cannot be maintained, especially with kidney disease, diuretics, blood-pressure medications, or older age.
Vision and Retinopathy
Rapid improvement in blood glucose may temporarily worsen diabetic retinopathy in susceptible patients. A rare association between semaglutide and non-arteritic anterior ischemic optic neuropathy (NAION) is also under regulatory and clinical study. Sudden painless vision loss is an emergency. Patients with diabetes or existing retinal disease should maintain eye care and report changes promptly.
Thyroid C-Cell Tumor Warning
Semaglutide, tirzepatide, and liraglutide caused thyroid C-cell tumors in rodents. It is unknown whether they cause medullary thyroid carcinoma in humans. These products are contraindicated with a personal or family history of MTC or MEN2. Report a new neck mass, persistent hoarseness, trouble swallowing, or shortness of breath.
Low Blood Sugar
GLP-1 medicines do not commonly cause hypoglycemia by themselves, but risk rises with insulin or sulfonylureas. Sweating, shaking, confusion, hunger, weakness, or blurred vision requires glucose testing and the patient’s prescribed hypoglycemia plan.
Pregnancy and Oral Contraception
Weight-loss medication should be stopped when pregnancy is recognized. Tirzepatide can reduce exposure to oral hormonal contraceptives during initiation and for four weeks after each dose increase; follow the label’s recommendation for non-oral or barrier contraception during those periods.
Anesthesia and Procedures
Delayed stomach emptying may increase aspiration risk. Tell the surgeon, anesthesiologist, dentist, and procedural team about the medication, dose, last dose, recent escalation, and GI symptoms. Follow their individualized instructions; do not assume every patient must stop for the same number of days.
Other Prescription Weight-Loss Medications
In addition to newer incretin-based therapies, several other medications and medical devices may be considered for weight management in appropriate patients. These options vary in effectiveness, mechanism of action, risks, and FDA-approved indications.
| Medication | How It Works | Approximate Average Weight Loss* | Potential Advantages | Important Disadvantages / Avoid When |
|---|---|---|---|---|
| Phentermine/topiramate ER (Qsymia®) | Sympathomimetic appetite suppression plus effects on appetite and cravings. | About 8%–10% or more at higher dose. | Effective oral option; may help cravings or migraine pattern. | Pregnancy/teratogenicity, glaucoma, hyperthyroidism, heart-rate effects, mood/cognitive effects; taper to avoid seizures. |
| Naltrexone/bupropion ER (Contrave®) | Reward/craving and appetite pathways. | About 5%–6%. | May help food cravings and selected mood/tobacco patterns. | Contraindicated with uncontrolled hypertension, seizure disorder, eating disorders, opioid use/dependence, MAOI use, or abrupt alcohol/sedative withdrawal. |
| Orlistat (Xenical®/Alli®) | Reduces intestinal fat absorption. | About 3%–5%. | Non-systemic mechanism; OTC lower-dose option. | Oily stool, urgency, fat-soluble vitamin deficiency, drug interactions; avoid in chronic malabsorption or cholestasis. |
| Phentermine | Stimulant-like appetite suppressant; FDA-approved short term. | Often about 3%–7% over short-term studies. | Low cost; oral; rapid appetite effect. | Controlled substance; insomnia, anxiety, heart rate/BP effects; avoid with significant cardiovascular disease, hyperthyroidism, glaucoma, pregnancy, MAOIs, or misuse risk. |
| Setmelanotide (Imcivree®) | MC4 receptor agonist. | Substantial in responsive genetic disorders. | Targets rare confirmed genetic obesity syndromes. | Not for common obesity; requires genetic/clinical eligibility and specialist care. |
| Metformin — off label for weight | Improves insulin sensitivity and reduces hepatic glucose production. | Usually modest, about 2%–5%. | Useful with prediabetes, insulin resistance, PCOS, or antipsychotic-associated gain in selected patients. | GI effects, B12 deficiency, kidney-related lactic-acidosis risk; not FDA-approved for weight loss. |
| Topiramate — off label | Reduces appetite and cravings through multiple neurologic pathways. | Often about 5%–10%. | May help migraine and binge-pattern symptoms in selected patients. | Pregnancy, cognitive slowing, tingling, kidney stones, glaucoma, metabolic acidosis; must taper. |
| Bupropion — off label | Norepinephrine/dopamine effects on appetite and reward. | Usually modest. | May help depression or smoking cessation in selected patients. | Seizure and eating-disorder contraindications; BP, anxiety, insomnia, and interaction risks. |
| Plenity® | Ingested hydrogel device that increases fullness. | Approximately 2%–4% beyond placebo in trials. | Non-systemic; BMI eligibility differs from medications. | Capsule burden, bloating, obstruction/swallowing concerns; less effective on average than incretin therapy. |
Note: *Approximate placebo-subtracted or total trial averages vary by study design, dose, population, diabetes status, adherence, and lifestyle intervention. These ranges are for comparison, not prediction.
Treating a Cause of Weight Gain
- Review medications associated with gain, such as certain antipsychotics, antidepressants, insulin, steroids, and seizure medications
- Evaluate sleep apnea, hypothyroidism, Cushing syndrome when clinically suspected, PCOS, menopause-related changes, and mobility limitations
- Treat binge-eating disorder, depression, trauma, alcohol use, or other behavioral health conditions appropriately
- Consider bariatric or metabolic surgery for eligible patients who need greater or more durable weight loss
Controlled Substance Policy
APNS does not prescribe, refill, or manage controlled substances. Phentermine is included for patient education and comparison only and is not presented as an APNS treatment option.
Lifestyle, Muscle Preservation, and Long-Term Maintenance
Nutrition
A reduced-calorie pattern is necessary for ongoing weight loss, but extreme restriction can increase fatigue, nutrient deficiency, gallstones, muscle loss, hair shedding, and regain. APNS does not require one diet. A dietitian can help tailor a Mediterranean, lower-carbohydrate, higher-protein, plant-forward, or other evidence-based pattern to medical needs and preferences.
- Prioritize adequate protein across meals to help preserve lean mass
- Use vegetables, fruit, legumes, and whole grains for fiber and micronutrients as tolerated
- Limit highly processed foods, sugar-sweetened beverages, and frequent calorie-dense snacks
- Plan smaller meals on GLP-1 therapy and stop eating when comfortably satisfied
- Maintain hydration and electrolytes when medically appropriate
- Avoid prolonged fasting if it promotes dizziness, hypoglycemia, binge eating, inadequate protein, or medication intolerance
Physical Activity and Strength
Aerobic activity supports cardiovascular health, insulin sensitivity, mood, and weight maintenance. Resistance training is especially important during medication-assisted weight loss because part of any weight reduction can come from lean mass. The plan should be adapted for arthritis, heart or lung disease, disability, or severe deconditioning.
- Aim for regular movement rather than an all-or-nothing plan
- Include resistance exercise two or more days weekly when medically appropriate
- Progress gradually and prioritize safe technique
- Increase daily steps or brief activity breaks
- Seek physical therapy or exercise-professional guidance when needed
Sleep, Stress, and Behavior
- Evaluate snoring, witnessed apnea, unrefreshing sleep, or daytime sleepiness
- Create consistent sleep and meal timing when possible
- Identify emotional eating, binge episodes, alcohol calories, and environmental triggers without shame
- Use structured follow-up, self-monitoring, and realistic goals
- Treat depression, anxiety, ADHD, eating disorders, or other conditions that interfere with care
When Goal Weight Is Reached
Reaching goal weight does not automatically mean the medication should stop at 12 months. Obesity is chronic, and discontinuation commonly increases hunger and weight regain. The clinician and patient should decide among continued maintenance dosing, dose reduction, switching medication, a supervised discontinuation trial, or another strategy based on benefits, side effects, health risks, preferences, cost, and weight trajectory.
Maintenance Priorities
- Preserve an appropriate—not underweight—BMI and adequate nutrition
- Maintain strength and lean mass
- Continue management of blood pressure, diabetes, lipids, fatty liver, and sleep apnea
- Use the lowest effective, tolerated regimen when appropriate
- Monitor for regain without blame and intervene early
- Continue permanent nutrition, activity, sleep, and behavioral supports
Low-Dose or “Microdosing” Maintenance
Some clinicians use the term “microdosing” to describe maintaining a patient on a lower dose, extending the interval between doses, or using a dose below a product’s labeled maintenance schedule after goal weight is reached. The term has no standardized medical definition. A lower individualized dose may reduce cost or side effects and may be sufficient for some patients, but evidence for nonstandard microdosing schedules is limited.
| Maintenance Approach | Potential Advantage | Important Limitation |
|---|---|---|
| Lowest FDA-labeled effective maintenance dose | Uses a studied product dose and preserves label-based administration. | Not every patient maintains appetite or weight control at the lowest labeled dose. |
| Gradual clinician-directed dose reduction | May identify the lowest dose that maintains weight while reducing adverse effects. | Regain may occur; monitoring and a predefined response plan are needed. |
| Dose below the labeled maintenance dose or extended interval (“microdosing”) | May be tolerated or affordable for an individual patient. | Off label; effectiveness, pharmacokinetics, and long-term outcomes are not well established. |
| Compounded personalized maintenance dose | Allows concentrations or increments unavailable commercially when compounding is legally and clinically justified. | Not FDA-approved or proven bioequivalent; concentration errors and inconsistent expectations are concerns. |
| Complete discontinuation trial | Avoids ongoing medication and cost. | Hunger and weight regain are common; stopping is not required merely because 12 months passed or goal weight was reached. |
Maintenance should be judged by weight trend, hunger and food noise, metabolic health, nutrition, muscle mass, side effects, cost, and patient preference. Patients should not cut tablets, divide single-dose pens, transfer medication, or improvise injection volumes unless the exact product and method were specifically prescribed and taught.
Medication Is Not a Failure of Lifestyle
Anti-obesity medication treats biological drivers of a chronic disease. Using long-term medication is no more a moral failure than using ongoing treatment for hypertension or diabetes.
Ready to take the next step?
Whether you’re just beginning your weight loss journey or looking for additional support after previous attempts, APNS is here to help. Our providers will work with you to develop a personalized treatment plan based on your health, goals, and individual needs.